Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults

Next Previous
Trial Profile

A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-administering AV7909 With Ciprofloxacin or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 20 Jul 2023 According to an Emergent BioSolutions media release, the company has received U.S. FDA Approval of CYFENDUS vaccine based on data from this study.
  • 24 Jun 2022 According to an Emergent BioSolutions media release, the company announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909, the rolling BLA submission, completed in April 2022, is based on data from phase 3 (VELOCITY) and this study. The Prescription Drug User Fee Act goal date for a decision by the FDA is in April 2023.
  • 25 Jun 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top